CLOVER CORPORATION LIMITED (CLV)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CLV - CLOVER CORPORATION LIMITED

FNArena Sector : Health & Nutrition
Year End: July
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.08
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.495

25 Jul
2024

0.010

OPEN

$0.49

2.06%

HIGH

$0.50

1,408

LOW

$0.49

TARGET
$0.60 21.2% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
EBO . EXL . MCP . SIG .
FNARENA'S MARKET CONSENSUS FORECASTS
CLV: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx 3.7 0.0 xxx
DPS (cps) xxx 1.5 N/A xxx
EPS Growth xxx - 13.3% N/A xxx
DPS Growth xxx 0.0% N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx 40.3% N/A xxx

Dividend yield today if purchased 3 years ago: 0.89%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

3.06

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 30/10 - ex-div 0.75c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx3.7
DPS All xxxxxxxxxxxxxxx1.5
Sales/Revenue xxxxxxxxxxxxxxx79.9 M
Book Value Per Share xxxxxxxxxxxxxxx40.2
Net Operating Cash Flow xxxxxxxxxxxxxxx6.7 M
Net Profit Margin xxxxxxxxxxxxxxx7.77 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx9.53 %
Return on Invested Capital xxxxxxxxxxxxxxx8.27 %
Return on Assets xxxxxxxxxxxxxxx7.02 %
Return on Equity xxxxxxxxxxxxxxx9.53 %
Return on Total Capital xxxxxxxxxxxxxxx12.94 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx2.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx2 M
Long Term Debt xxxxxxxxxxxxxxx10 M
Total Debt xxxxxxxxxxxxxxx12 M
Goodwill - Gross xxxxxxxxxxxxxxx2 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx9 M
Price To Book Value xxxxxxxxxxxxxxx2.71

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx1.6 M
Capex % of Sales xxxxxxxxxxxxxxx2.05 %
Cost of Goods Sold xxxxxxxxxxxxxxx56 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx14 M
Research & Development xxxxxxxxxxxxxxx3 M
Investments - Total xxxxxxxxxxxxxxx12 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

UBS

22/03/2024

3

Neutral

$0.60

21.21%

The UBS target for Clover falls to 60c from 85c due to material medium-term EPS forecast downgrades, partially offset by less material long-term cuts as the broker incorporates a sales and margin recovery over time.

These changes by the analyst follow 1H results and a 2H outlook showing softer-than-expected customer reordering post sales made via China's Singles Day, reflecting soft demand. 

There were also appreciably softer gross margins, down -4 percentage points year-on-year, driven by increased price competition in the market and customer mix impacts, explains the broker.

The Neutral rating is unchanged.

FORECAST
UBS forecasts a full year FY24 EPS of 0.00 cents.
UBS forecasts a full year FY25 EPS of 2.00 cents.

EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Taylor Collison

xx/xx/xxxx

1

xxxxxxx xx xxxxxxxxxxx xxx xxxx xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Petra Capital

20/03/2024

1

Buy

$0.98

97.98%

a2 Milk ((A2M)) estimates that the infant formula market in China declined by -14% by value (-11% by volume) in 1H24, with English-labelled product proving more resilient than Chinese-labelled product.

While Petra Capital does not expect Clover to be immune from weaker 1H24 sales in China IF, there are mitigating factors. First and foremost is the fact that Clover reiterated its guidance for FY24 at its AGM in late November 2023.

That said, beyond FY24, the broker sees greater downside risk to forecasts based on an updated view that China, which accounts for  some 50% of global IF demand, will take longer to recover than previously thought.

Petra cuts its FY24-26 earnings forecasts by -2%, -21% and -15%, and target to 98c from $1.10. Buy retained on Clover's competitive position and long-term growth prospects.

FORECAST
Petra Capital forecasts a full year FY24 dividend of 1.50 cents and EPS of 3.00 cents.
Petra Capital forecasts a full year FY25 dividend of 2.00 cents and EPS of 4.40 cents.

CLV STOCK CHART